The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical ...

The finding could reduce the need for unnecessary medication and screening appointments in those deemed low risk for uveitis.

Researchers evaluated the efficacy and safety of ixekizumab over a 16-week period for the treatment of juvenile psoriatic arthritis or enthesitis-related arthritis.

The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical ...

Discover how DMARD use has evolved in juvenile idiopathic arthritis treatment, with biologics like adalimumab rising as conventional therapies decline.

Adults and children with noninfectious uveitis had lower health-related quality of life than those without the condition, a ...

More information: Bruno Fautrel et al, EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's ...

More information: Priyanka Yalamanchili et al, Trends in New Use of Disease‐Modifying Antirheumatic Drugs in Juvenile ...

The consensus based term for a rheumatic joint disorder in childhood is “juvenile idiopathic arthritis (JIA)”, and not “juvenile rheumatic coxitis.” [note: the author points out a mistake ...

The use of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for treating juvenile idiopathic arthritis (JIA) rose sharply from 2001 to 2022, while the use of ...